Fluoroquinolones in animal health
- 1 February 1996
- journal article
- review article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 19 (1), 1-14
- https://doi.org/10.1111/j.1365-2885.1996.tb00001.x
Abstract
The fluoroquinolones are a series of synthetic antibacterial agents that are undergoing extensive investigation for both human and veterinary use in the treatment of a variety of bacterial infections. These agents work through the inhibition of DNA gyrase, interfering with the supercoiling of bacterial chromosomal material. As a result, these agents are rapidly bactericidal primarily against gram-negative bacteria, mycoplasma, and some gram-positive bacteria, with most having little to no activity against group D streptococci and obligate anaerobic bacteria. Resistance develops slowly and is almost always chromosomal and not plasmid-mediated. However, development of resistance to the fluoroquinolones and transfer of that resistance among animal and human pathogens have become a hotly debated issue among microbiologists. The fluoroquinolones are a current antimicrobial class whose use in veterinary medicine is being scrutinized. From a pharmacokinetic perspective, these agents are variably but well absorbed from the gastrointestinal tract and almost completely absorbed from parenteral injection sites, and they are well distributed to various tissues in the body. The fluoroquinolones are metabolized and renally excreted, with many of them having approximately equal excretion by the hepatic and the renal excretory systems. The primary toxicity observed at therapeutic doses involves the gastrointestinal system and phototoxicity, although at higher doses central nervous system toxicity and ocular cataracts are observed. Administration to immature animals may result in erosive arthropathies at weight-bearing joints, and administration of high doses to pregnant animals results in maternotoxicity and occasionally embryonic death. The fluoroquinolones are approved for indications such as urinary tract infections and soft tissue infections in dogs and cats and colibacillosis in poultry. Approval for bovine respiratory disease in the United States is being sought. Other indications for which the fluoroquinolones have been used in animal health include deep-seated infections, prostatitis, and other bacterial infections resistant to standard antimicrobial therapy.Keywords
This publication has 96 references indexed in Scilit:
- Mode of action of the new quinolones: New dataEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Synergy and antagonism of combinations with quinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Newly documented antimicrobial activity of quinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Use of quinolones for treatment of ear and eye infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Pharmacokinetics of quinolones: Newer aspectsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Immunological aspects of new quinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Ciprofloxacin Pharmacokinetics After a Standard or High‐Fat/High‐Calcium BreakfastThe Journal of Clinical Pharmacology, 1989
- Pharmacokinetic Disposition of Quinolones in Human Body Fluids and TissuesClinical Pharmacokinetics, 1989
- The Use of Quinolones in Respiratory Tract InfectionsDrugs, 1987
- Comparative Pharmacokinetics of New QuinolonesDrugs, 1987